<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app57.us.archive.org';v.server_ms=104;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml', '20180712195835')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20180712195835/https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20180712195835/https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20180712195835" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610070631/https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml" title="10 Jun 2018"><strong>Jun</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 19:58:35 Jul 12, 2018">JUL</td>
		  <td class="f" nowrap="nowrap">Aug</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610070631/https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml" title="07:06:31 Jun 10, 2018"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 19:58:35 Jul 12, 2018">12</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930192949/https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 19:58:35 Jul 12, 2018">2018</td>
		  <td class="f" nowrap="nowrap">2019</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20180712195835*/https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml" title="See a list of every capture for this URL">6 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 12 Jul 2018</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archiveteam);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/archiveteam" target="_new"><span class="wm-title">Archive Team</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  <img align=right src="http://archiveteam.org/images/e/e6/Archiveteam.jpg" width=200> Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded into a large amount of related projects for saving online and digital history.
<p>
History is littered with hundreds of conflicts over the future of a community, group, location or business that were "resolved" when one of the parties stepped ahead and destroyed what was there. With the original point of contention destroyed, the debates would fall to the wayside. Archive Team believes that by duplicated condemned data, the conversation and debate can continue, as well as the richness and insight gained by keeping the materials. Our projects have ranged in size from a single volunteer downloading the data to a small-but-critical site, to over 100 volunteers stepping forward to acquire terabytes of user-created data to save for future generations.
<p>
The main site for Archive Team is at <a href="http://www.archiveteam.org">archiveteam.org</a> and contains up to the date information on various projects, manifestos, plans and walkthroughs.
<p>
This collection contains the output of many Archive Team projects, both ongoing and completed. Thanks to the generous providing of disk space by the Internet Archive, multi-terabyte datasets can be made available, as well as in use by the <a href="http://archive.org/web/web.php">Wayback Machine</a>, providing a path back to lost websites and work. 
<p>
Our collection has grown to the point of having sub-collections for the type of data we acquire. If you are seeking to browse the contents of these collections, the Wayback Machine is the best first stop. Otherwise, you are free to dig into the stacks to see what you may find.
<p>
<b>The Archive Team Panic Downloads</b> are full pulldowns of currently extant websites, meant to serve as emergency backups for needed sites that are in danger of closing, or which will be missed dearly if suddenly lost due to hard drive crashes or server failures. 
<p>
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archivebot)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/archivebot" target="_new"><span class="wm-title">ArchiveBot: The Archive Team Crowdsourced Crawler</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  ArchiveBot is an IRC bot designed to automate the archival of smaller websites (e.g. up to a few hundred thousand URLs). You give it a URL to start at, and it grabs all content under that URL, records it in a WARC, and then uploads that WARC to ArchiveTeam servers for eventual injection into the Internet Archive (or other archive sites).
<p>
To use ArchiveBot, drop by #archivebot on EFNet. To interact with ArchiveBot, you issue commands by typing it into the channel. Note you will need channel operator permissions in order to issue archiving jobs. The dashboard shows the sites being downloaded currently.
<p>
There is a dashboard running for the archivebot process at <a href="http://www.archivebot.com">http://www.archivebot.com</a>.
<p>
ArchiveBot's source code can be found at <a href="https://github.com/ArchiveTeam/ArchiveBot">https://github.com/ArchiveTeam/ArchiveBot</a>.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10384?contentType=xml","2018-07-12",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Extragonadal germ cell tumours.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Genitourinary Tumour Team. Extragonadal germ cell tumours. Edmonton (Alberta): CancerControl Alberta; 2013 Apr. 8 p.&amp;nbsp;(Clinical practice guideline; no. GU-007).&amp;nbsp; [24 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Diagnosis</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>If a patient presents with undifferentiated adenocarcinoma of unknown origin, copy number of chromosome i12p should be performed. </li>
    <li>Lactate dehydrogenase (LDH), alpha fetoprotein (AFP) and gonadotropin (hCG) should be assessed. </li>
    <li>Patients should be classified and treated based on prognosis (International Germ Cell Cancer Collaborative Group [IGCCCG], 1997) </li>
</ul>
<p><strong>Table. Prognostic Factors for Germ Cell Tumours (GCTs)</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Prognostic Factors for Germ Cell Tumours (GCTs)&quot;>
    <thead>
        <tr>
            <th valign=&quot;top&quot;>Prognosis</th>
            <th valign=&quot;top&quot;>Non-seminoma</th>
            <th valign=&quot;top&quot;>Seminoma</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>Good</td>
            <td valign=&quot;top&quot;>Primary extragonadal retroperitoneal
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>and low markers: AFP &amp;lt;1,000 ng/ml </li>
                <li>and &amp;beta;-hCG &amp;lt;1,000 ng/ml (&amp;lt;5,000 IU/I) </li>
                <li>and LDH &amp;lt;1.5 x normal level </li>
                <li>and no non-pulmonary visceral metastases </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Any primary localization </li>
                <li>Any marker level </li>
                <li>No non-pulmonary visceral metastases </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Intermediate</td>
            <td valign=&quot;top&quot;>Primary extragonadal retroperitoneal
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>and AFP 1,000&amp;ndash;10,000 ng/ml </li>
                <li><strong>and/or</strong> &amp;beta;-hCG 1,000&amp;ndash;10,000 ng/ml (5,000-50,000 IU/l) </li>
                <li><strong>and/or</strong> LDH 1.5&amp;ndash;10 x normal level </li>
                <li><strong>and</strong> no non-pulmonary visceral metastases </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Any primary localization </li>
                <li>Presence of non-pulmonary visceral metastases (liver, CNS, bone, intestinum) </li>
                <li>Any marker level </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Poor</td>
            <td valign=&quot;top&quot;>Primary mediastinal GCT with or without testis or primary retroperitoneal tumour
            <ul style=&quot;list-style-type: disc;&quot;>
                <li><strong>and</strong> presence of non-pulmonary visceral metastases (liver, CNS, bone, intestinum) </li>
                <li><strong>and/or</strong> &quot;high markers&quot;
                <ul style=&quot;list-style-type: disc;&quot;>
                    <li>AFP &amp;gt;10,000 ng/ml </li>
                    <li>&amp;beta;-hCG &amp;gt;10,000 ng/ml (50,000 IU/l) </li>
                </ul>
                </li>
                <li><strong>or</strong> LDH &amp;gt;10 x normal level </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>N/A</td>
        </tr>
    </tbody>
</table>
<p class=&quot;Note&quot;>AFP, alpha fetoprotein; &amp;beta;-hCG, beta human chorionic gonadotropin; CNS, central nervous system; GCT, germ cell tumour; LDH, lactate dehydrogenase</p>
<p><strong>Management</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Patients should be considered for clinical trials. </li>
    <li>Bleomycin, etoposide and cisplatin (BEP) or etoposide, ifosfamide, cisplatin (VIP) is recommended as first-line chemotherapy, with the number of cycles given based on risk category. </li>
    <li>For failure or relapse on either of these regimens and good risk disease, high dose chemotherapy and peripheral blood stem cell transplantation can be given. Recommended agents for high dose chemotherapy include ifosfamide, vinblastine, carboplatin, etoposide and paclitaxel. </li>
    <li>Patients who are classified as poor risk at relapse should be considered early for high dose chemotherapy and peripheral blood stem cell transplantation, as they may not be well enough to consider this treatment in the third line setting. </li>
    <li>Patients with mediastinal germ cell tumours (GCTs) who relapse have poor prognosis. Transplant should not routinely be offered to these patients. However, depending on the results from salvage chemotherapy, patient performance status, individual factors and patient's desire to pursue the transplant, it may be considered only after an honest discussion between the clinician and patient as the chance of long term remission and cure are very low. </li>
    <li>After the completion of chemotherapy, strong consideration for retroperitoneal lymph node dissection should be given in those patients with retroperitoneal primary GCTs. </li>
    <li>After the completion of chemotherapy, surgery to resect any residual masses should be strongly considered in those patients with mediastinal primary GCTs. </li>
</ol>
<p><strong>Table. Suggested Follow-up Schedule for Germ Cell Tumours</strong> (British Columbia Cancer Agency, 2005)</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Suggested Follow-up Schedule for Germ Cell Tumours&quot;>
    <thead>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;>Group</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot; rowspan=&quot;2&quot;>Clinical Examination and Diagnostics</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;6&quot;>Frequency of Exam (Months)</th>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Year 1</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Year 2</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Year 3</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Year 4</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Year 5</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Years 5&amp;ndash;10</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <th valign=&quot;top&quot; rowspan=&quot;3&quot;>Good Prognosis</th>
            <td valign=&quot;top&quot;>LDH, AFP, hCG, clinical exam</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>X-ray of the chest or CT scan of chest (if supradiaph. disease)</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3&amp;ndash;6*</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>4</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>CT scan of the abdomen/pelvis</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>4</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot; rowspan=&quot;3&quot;>Intermediate and Poor Prognosis</th>
            <td valign=&quot;top&quot;>LDH, AFP, hCG, clinical exam</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>X-ray of the chest or CT scan of chest (if supradiaph. disease)</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3&amp;ndash;6*</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3&amp;ndash;6*</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>4&amp;ndash;6*</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>CT scan of the abdomen/pelvis</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>3</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>4</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>6</td>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
    </tbody>
</table>
<p class=&quot;Note&quot;>AFP, alpha fetoprotein; hCG, human chorionic gonadotropin; CT, computed tomography; LDH, lactate dehydrogenase</p>
<p class=&quot;Note&quot;>*Depending on the presence of intrathoracic disease.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Extragonadal germ cell tumours (GCTs) </p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Diagnosis"/>
      <fieldvalue value="Evaluation"/>
      <fieldvalue value="Management"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Surgery"/>
      <fieldvalue value="Urology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To provide guidance on appropriate management strategies for patients with primary mediastinal or retroperitoneal germ cell tumours (GCTs) </p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Postpubertal patients with primary mediastinal or retroperitoneal germ cell tumours (GCTs)</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Diagnosis/Evaluation</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Obtaining copy number of chromosome i12p in patients with undifferentiated adenocarcinoma of unknown origin </li>
    <li>Laboratory testing: lactate dehydrogenase (LDH), alpha fetoprotein (AFP) and gonadotropin (hCG) </li>
    <li>Classification and treatment of patients based on prognosis </li>
</ol>
<p><strong>Treatment/Management</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Consideration for clinical trials </li>
    <li>Bleomycin, etoposide and cisplatin (BEP) or etoposide, ifosfamide, cisplatin (VIP) as first-line chemotherapy </li>
    <li>High-dose chemotherapy (e.g., ifosfamide, vinblastine, carboplatin, etoposide and paclitaxel) and peripheral blood stem cell transplantation for treatment failure or relapse </li>
    <li>Retroperitoneal lymph node dissection in patients with retroperitoneal primary germ cell tumours (GCTs) </li>
    <li>Surgery to resect residual masses </li>
    <li>Follow-up examinations based on prognosis </li>
</ol></div>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Survival rate (2-year, 5-year, overall, progression-free) </li>
    <li>Remission rate </li>
    <li>Treatment-related toxicity </li>
    <li>Surgical complications, including intra-operative deaths </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Research Questions</strong></p>
<p>Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (patient or population, intervention, comparisons, outcomes).</p>
<p><strong>Guideline Question</strong></p>
<p>What are the appropriate management strategies for patients with primary mediastinal or retroperitoneal germ cell tumours (GCTs)?</p>
<p><strong>Search Strategy</strong></p>
<p>The PubMed database was searched using the terms (retroperitoneal OR mediastinal) AND germ cell AND primary, published between 1946 and 2012 April. Results were limited to clinical trials, studies in humans, meta-analyses, and practice guidelines. The Medline database was then searched for relevant literature using the MeSH terms &quot;Neoplasm, germ cell and embryonal&quot; with subheadings drug therapy, radiotherapy, therapy, and surgery, combined with &quot;extragonadal.&quot; Results were limited to literature published between 1946 and 2012 April. Studies involving fewer than ten patients with extragonadal GCTs, as well as single case studies, were excluded.</p>
<p>Websites of the following guideline developers were searched for relevant guidelines: National Comprehensive Cancer Network (NCCN), British Columbia Cancer Agency (BCCA), European Society of Medical Oncology (ESMO), National Institutes of Health and Care Excellence (NICE), American Society of Clinical Oncology (ASCO), Scottish Intercollegiate Guidelines Network (SIGN), Cancer Council Australia (CCA) and Cancer Care Ontario (CCO).</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Not stated"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Genitourinary Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Utilization Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the GURU Handbook (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong>Evidence Tables</strong></p>
<p>Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic are assessed by the KM Specialist using portions of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (<a href=&quot;http://www.agreetrust.org&quot; title=&quot;AGREE Trust Web site&quot;>http://www.agreetrust.org</a>) and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Formulating Recommendations</strong></p>
<p>The working group members formulated the guideline recommendations based on the evidence synthesized by the Knowledge Management (KM) Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the Guideline Utilization Resource Unit Handbook (see the &quot;Availability of Companion Documents&quot; field), the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.</p>
<p>The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the Guideline Utilization Resource Unit (GURU) does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This guideline was reviewed and endorsed by the Alberta Provincial Genitourinary Tumour Team.</p>
<p>When the draft guideline document has been completed, revised, and reviewed by the Knowledge Management (KM) Specialist and the working group members, it is sent to all members of the Provincial Tumour Team for review and comment. This step ensures that those intended to use the guideline have the opportunity to review the document and identify potential difficulties for implementation before the guideline is finalized. Depending on the size of the document, and the number of people it is sent to for review, a deadline of one to two weeks will usually be given to submit any feedback. Ideally, this review will occur prior to the annual Provincial Tumour Team meeting, and a discussion of the proposed edits will take place at the meeting. The working group members will then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it will be officially endorsed by the Provincial Tumour Team Lead and the Executive Director of Provincial Tumour Programs.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="98" ordby="605" id="425" name="References Supporting the Recommendations" type="citation">
      <fieldvalue value="<table><tr><td>British Columbia Cancer Agency. Testis. Cancer management guidelines-genitourinary. Vancouver (BC): British Columbia Cancer Agency; 2005 Jun. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997 Feb;15(2):594-603. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9053482&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of evidence supporting the recommendations is not specifically stated.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Appropriate diagnosis and management of extragonadal germ cell tumours (GCTs) </p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Adverse effects of chemotherapy, including gastrointestinal, hepatobiliary, genitourinary, and hematologic toxicity </li>
    <li>Researchers reported a 25-year single institution experience of post-chemotherapy surgery for 158 patients with mediastinal primary non-seminoma germ cell tumours (GCTs). Intra-operative deaths occurred in 6% of patients, 90% of which were due to respiratory failure. Post-operative complications occurred in 18% of patients. </li>
</ul>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations contained in this guideline are a consensus of the Alberta Provincial Genitourinary Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Present the guideline at the local and provincial tumour team meetings and weekly rounds. </li>
    <li>Post the guideline on the Alberta Health Services Web site. </li>
    <li>Send an electronic notification of the new guideline to all members of CancerControl Alberta. </li>
</ul>"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Genitourinary Tumour Team. Extragonadal germ cell tumours. Edmonton (Alberta): CancerControl Alberta; 2013 Apr. 8 p.&amp;nbsp;(Clinical practice guideline; no. GU-007).&amp;nbsp; [24 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2013 Apr"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="CancerControl Alberta - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>CancerControl Alberta</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Alberta Provincial Genitourinary Tumour Team</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Members of the Alberta Provincial Genitourinary Tumour Team include medical oncologists, radiation oncologists, urologists, pathologists, nurses, and pharmacists.</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Participation of members of the Alberta Provincial Genitourinary Tumour Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. There was no direct industry involvement in the development or dissemination of this guideline. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Genitourinary Tumour Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Available from the <a href=&quot;http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu007-extragonadal-gct.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Alberta Health Services Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Guideline utilization resource unit handbook. Edmonton (Alberta): CancerControl Alberta; 2013 Jan. 5 p. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on August 12, 2014. The information was verified by the guideline developer on September 25, 2014.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 19:58:35 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:07:46 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 41.162 (3)
  esindex: 0.008
  captures_list: 59.515
  CDXLines.iter: 13.375 (3)
  PetaboxLoader3.datanode: 40.906 (4)
  exclusion.robots: 0.325
  exclusion.robots.policy: 0.311
  RedisCDXSource: 1.545
  load_resource: 22.221
-->